Get the Stockscreener App
9.03
8.80%
0.73
Pre-market:
8.92
-0.11
-1.22%
Arvinas Inc stock is traded at $9.03, with a volume of 8.08M.
It is up +8.80% in the last 24 hours and down -49.69% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$8.30
Open:
$8.39
24h Volume:
8.08M
Relative Volume:
5.67
Market Cap:
$621.01M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.9336
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-48.39%
1M Performance:
-49.69%
6M Performance:
-63.16%
1Y Performance:
-80.15%
1-Day Range:
$8.12
$9.14
1-Week Range:
$7.9136
$18.93
52-Week Range:
$7.9136
$46.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
9.03 | 621.01M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas’s SWOT analysis: biotech stock faces pivotal trials amid competition - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56% - Simply Wall St
Arvinas downgraded to Neutral from Buy at Goldman Sachs - TipRanks
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Pfizer, Arvinas post mixed late-stage trial results for breast cancer therapy - MSN
Arvinas stock draws Wedbush downgrade (ARVN:NASDAQ) - Seeking Alpha
Street View: Arvinas' breast cancer drug's trial results a letdown - TradingView
Arvinas price target lowered to $20 from $82 at BMO Capital - TipRanks
Arvinas (NASDAQ:ARVN) Receives "Buy" Rating from HC Wainwright - MarketBeat
Cautious Outlook on Arvinas Holding: Hold Rating Maintained Amid Mixed VERITAC-2 Trial Results - TipRanks
Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform - MarketBeat
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Mixed Phase III Results for Arvinas, Pfizer’s Breast Cancer PROTAC Degrader - Inside Precision Medicine
Arvinas and Pfizer’s vepdegestrant meets primary endpoint in VERITAC-2 trial - World Pharmaceutical Frontiers
Arvinas (NASDAQ:ARVN) Hits New 12-Month LowHere's Why - MarketBeat
ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study - Nasdaq
Wedbush cuts Arvinas to Neutral as VERITAC-2 shows monotherapy strategy limited - TipRanks
BMO Capital cuts Arvinas stock target to $20 from $82 - Investing.com India
Arvinas stock holds Buy rating, $81 target from H.C. Wainwright - Investing.com India
Arvinas stock holds Buy rating, $81 target from H.C. Wainwright By Investing.com - Investing.com South Africa
BMO Capital cuts Arvinas stock target to $20 from $82 By Investing.com - Investing.com South Africa
Arvinas (NASDAQ:ARVN) Cut to "Neutral" at Wedbush - MarketBeat
Arvinas Holding’s Promising Phase 3 Results and Strategic Focus Support Buy Rating - TipRanks
Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57 - Marketscreener.com
BofA lowers Arvinas price target to $28, calls selloff ‘overdone’ - TipRanks
Arvinas Holding Company: Strategic Positioning and Market Opportunities Amidst Challenges - TipRanks
BTIG maintains Buy on Arvinas stock, price target at $69 By Investing.com - Investing.com South Africa
Arvinas Holding Company: Promising ESR1m Subgroup Results and Strong Financial Position Support Buy Rating - TipRanks
Arvinas price target lowered to $26 from $60 at Wells Fargo - TipRanks
BTIG maintains Buy on Arvinas stock, price target at $69 - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Arvinas’ (ARVN) Buy Rating Reaffirmed at HC Wainwright - Defense World
Arvinas (NASDAQ:ARVN) Lowered to “Market Perform” Rating by Oppenheimer - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Contrasting Arvinas (NASDAQ:ARVN) & Elevai Labs (NASDAQ:ELAB) - Defense World
Arvinas shares halved as vepdegestrant underwhelms - The Pharma Letter
Citigroup Lowers Arvinas (NASDAQ:ARVN) Price Target to $19.00 - MarketBeat
Arvinas Plunges 40% After Pfizer-Partnered Drug Disappoints - MSN
Arvinas/Pfizer’s Vepdegestrant Misses Best Case In Phase III - Citeline News & Insights
Citi cuts Arvinas stock target to $10 from $19, maintains neutral - Investing.com
Arvinas stock rating cut to Perform at Oppenheimer By Investing.com - Investing.com Australia
Health: Pfizer-Arvinas' breast cancer treatment shows mixed results in late-stage study - Gulf Digital News
Why Pfizer's Cancer Partner Just Plummeted More Than 50% - Investor's Business Daily
Citi cuts Arvinas stock target to $10 from $19, maintains neutral By Investing.com - Investing.com South Africa
Arvinas Holding Company: Hold Rating Due to VERITAC-2 Trial Underperformance and Limited Market Uptake Potential - TipRanks
Arvinas price target lowered to $10 from $19 at Citi - TipRanks
Pfizer stock, Arvinas stock slip on breast cancer data (PFE:NYSE) - Seeking Alpha
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Benzinga
Promising Clinical Trial Results and Market Potential Drive Buy Rating for Arvinas Holding Company - TipRanks
Arvinas downgraded at Oppenheimer after trial misses co-primary endpoint - TipRanks
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):